{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:26:02Z","timestamp":1773275162765,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":3416,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1038\/sj.mt.6300147","type":"journal-article","created":{"date-parts":[[2007,5,15]],"date-time":"2007-05-15T14:23:40Z","timestamp":1179239020000},"page":"1174-1181","source":"Crossref","is-referenced-by-count":6,"title":["Anti-CD25 Targeted Killing of Bicistronically Transduced Cells: A Novel Safety Mechanism Against Retroviral Genotoxicity"],"prefix":"10.1016","volume":"15","author":[{"given":"Shobha","family":"Ramsubir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Yoshimitsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A","family":"Medin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/sj.mt.6300147_bib1","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1126\/science.1070104","article-title":"Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning","volume":"296","author":"Aiuti","year":"2002","journal-title":"Science"},{"key":"10.1038\/sj.mt.6300147_bib2","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(04)17590-9","article-title":"Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector","volume":"364","author":"Gaspar","year":"2004","journal-title":"Lancet"},{"key":"10.1038\/sj.mt.6300147_bib3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0163-7258(98)00020-5","article-title":"Viral vectors for gene therapy","volume":"80","author":"Robbins","year":"1998","journal-title":"Pharmacol Ther"},{"key":"10.1038\/sj.mt.6300147_bib4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"10.1038\/sj.mt.6300147_bib5","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMra032207","article-title":"Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency","volume":"350","author":"McCormack","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1038\/sj.mt.6300147_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ymthe.2003.10.013","article-title":"Chance or necessity? Insertional mutagenesis in gene therapy and its consequences","volume":"9","author":"Baum","year":"2004","journal-title":"Mol Ther"},{"key":"10.1038\/sj.mt.6300147_bib7","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N Engl J Med"},{"key":"10.1038\/sj.mt.6300147_bib8","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0925-4439(98)00012-X","article-title":"Immunohistochemical characterization of transgenic mice highly expressing human lysosomal alpha-galactosidase","volume":"1406","author":"Kase","year":"1998","journal-title":"Biochim Biophys Acta"},{"key":"10.1038\/sj.mt.6300147_bib9","doi-asserted-by":"crossref","first-page":"7917","DOI":"10.1073\/pnas.93.15.7917","article-title":"Correction in trans for Fabry disease: expression, secretion and uptake of alpha-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector","volume":"93","author":"Medin","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/sj.mt.6300147_bib10","doi-asserted-by":"crossref","first-page":"7515","DOI":"10.1073\/pnas.120177997","article-title":"Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells","volume":"97","author":"Takenaka","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/sj.mt.6300147_bib11","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.gt.3302839","article-title":"Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem\/progenitor cells","volume":"14","author":"Yoshimitsu","year":"2007","journal-title":"Gene Ther"},{"key":"10.1038\/sj.mt.6300147_bib12","doi-asserted-by":"crossref","first-page":"16909","DOI":"10.1073\/pnas.0407572101","article-title":"Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors","volume":"101","author":"Yoshimitsu","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/sj.mt.6300147_bib13","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1073\/pnas.061020598","article-title":"Preselective gene therapy for Fabry disease","volume":"98","author":"Qin","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/sj.mt.6300147_bib14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0092-8674(93)90152-G","article-title":"The IL-2\/IL-2 receptor system: a current overview","volume":"73","author":"Taniguchi","year":"1993","journal-title":"Cell"},{"key":"10.1038\/sj.mt.6300147_bib15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/cyto.2001.0862","article-title":"Signaling domains of the interleukin 2 receptor","volume":"14","author":"Gaffen","year":"2001","journal-title":"Cytokine"},{"key":"10.1038\/sj.mt.6300147_bib16","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/0165-0173(95)00015-1","article-title":"Interleukin-2 as a neuroregulatory cytokine","volume":"21","author":"Hanisch","year":"1995","journal-title":"Brain Res Brain Res Rev"},{"key":"10.1038\/sj.mt.6300147_bib17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1182\/blood.V91.1.165","article-title":"Further analysis of interleukin-2 receptor subunit expression on the different human peripheral blood mononuclear cell subsets","volume":"91","author":"David","year":"1998","journal-title":"Blood"},{"key":"10.1038\/sj.mt.6300147_bib18","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.4049\/jimmunol.135.5.3172","article-title":"Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro","volume":"135","author":"Rubin","year":"1985","journal-title":"J Immunol"},{"key":"10.1038\/sj.mt.6300147_bib19","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.4049\/jimmunol.126.4.1393","article-title":"A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells","volume":"126","author":"Uchiyama","year":"1981","journal-title":"J Immunol"},{"key":"10.1038\/sj.mt.6300147_bib20","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/0006-291X(85)91981-3","article-title":"Characterization of a Saponaria officinalis seed ribosome-inactivating protein: immunoreactivity and sequence homologies","volume":"129","author":"Lappi","year":"1985","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1038\/sj.mt.6300147_bib21","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/nar\/25.3.518","article-title":"Polynucleotide:adenosine glycosidase activity of ribosome-inactivating proteins: effect on DNA, RNA and poly(A)","volume":"25","author":"Barbieri","year":"1997","journal-title":"Nucleic Acids Res"},{"key":"10.1038\/sj.mt.6300147_bib22","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2005-11-4757","article-title":"Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7\/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25","volume":"108","author":"Zhang","year":"2006","journal-title":"Blood"},{"key":"10.1038\/sj.mt.6300147_bib23","first-page":"752","article-title":"Tumor burden and serum level of soluble CD25, CD8, CD23, CD54 and CD44 in non-Hodgkin's lymphoma","volume":"83","author":"Perez-Encinas","year":"1998","journal-title":"Haematologica"},{"key":"10.1038\/sj.mt.6300147_bib24","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s10545-005-0258-8","article-title":"Trends in haematopoietic cell transplantation for inborn errors of metabolism","volume":"29","author":"Boelens","year":"2006","journal-title":"J Inherit Metab Dis"},{"key":"10.1038\/sj.mt.6300147_bib25","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nrm1423","article-title":"The cell biology of lysosomal storage disorders","volume":"5","author":"Futerman","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1038\/sj.mt.6300147_bib26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1046\/j.1523-5394.2001.009002071.x","article-title":"Monoclonal antibody therapy for lymphoma: an update","volume":"9","author":"Dillman","year":"2001","journal-title":"Cancer Pract"},{"key":"10.1038\/sj.mt.6300147_bib27","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00277-003-0752-8","article-title":"Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects","volume":"83","author":"Gokbuget","year":"2004","journal-title":"Ann Hematol"},{"key":"10.1038\/sj.mt.6300147_bib28","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1038\/sj.mt.6300147_bib29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/sonc.2002.30145","article-title":"Rituximab: ongoing and future clinical development","volume":"29","author":"Grillo-Lopez","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1038\/sj.mt.6300147_bib30","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2165\/00003495-200666060-00005","article-title":"Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia","volume":"66","author":"Cvetkovic","year":"2006","journal-title":"Drugs"},{"key":"10.1038\/sj.mt.6300147_bib31","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1089\/10430340050015798","article-title":"Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies","volume":"11","author":"Introna","year":"2000","journal-title":"Hum Gene Ther"},{"key":"10.1038\/sj.mt.6300147_bib32","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/sj.gt.3302705","article-title":"The CD20\/alphaCD20 'suicide' system: novel vectors with improved safety and expression profiles and efficient elimination of CD20-transgenic T cells","volume":"13","author":"van Meerten","year":"2006","journal-title":"Gene Ther"},{"key":"10.1038\/sj.mt.6300147_bib33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/10430340460732463","article-title":"Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease","volume":"15","author":"Serafini","year":"2004","journal-title":"Hum Gene Ther"},{"key":"10.1038\/sj.mt.6300147_bib34","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1200\/JCO.2000.18.8.1622","article-title":"Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies","volume":"18","author":"Kreitman","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1038\/sj.mt.6300147_bib35","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1182\/blood.V94.10.3340.422k19_3340_3348","article-title":"Responses in refractory hairy cell leukemia to a recombinant immunotoxin","volume":"94","author":"Kreitman","year":"1999","journal-title":"Blood"},{"key":"10.1038\/sj.mt.6300147_bib36","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1399-0012.2005.00488.x","article-title":"Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study","volume":"20","author":"Lin","year":"2006","journal-title":"Clin Transplant"},{"key":"10.1038\/sj.mt.6300147_bib37","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0301-472X(03)00228-5","article-title":"Humanized anti-CD25 monoclonal antibody for prophylaxis of graft-vs-host disease (GvHD) in haploidentical bone marrow transplantation without ex vivo T-cell depletion","volume":"31","author":"Chen","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1038\/sj.mt.6300147_bib38","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1158\/1078-0432.CCR-06-0053","article-title":"Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells","volume":"12","author":"Fecci","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1038\/sj.mt.6300147_bib39","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4049\/jimmunol.177.1.84","article-title":"IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice","volume":"177","author":"Knutson","year":"2006","journal-title":"J Immunol"},{"key":"10.1038\/sj.mt.6300147_bib40","first-page":"3128","article-title":"Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody","volume":"59","author":"Onizuka","year":"1999","journal-title":"Cancer Res"},{"key":"10.1038\/sj.mt.6300147_bib41","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood-2004-05-1709","article-title":"Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody","volume":"105","author":"Zhang","year":"2005","journal-title":"Blood"},{"key":"10.1038\/sj.mt.6300147_bib42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1034\/j.1600-0609.2002.01692.x","article-title":"Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study","volume":"69","author":"Jaeger","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1038\/sj.mt.6300147_bib43","first-page":"272","article-title":"Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia","volume":"91","author":"Claviez","year":"2006","journal-title":"Haematologica"},{"key":"10.1038\/sj.mt.6300147_bib44","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/nbt1216","article-title":"Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration","volume":"24","author":"Montini","year":"2006","journal-title":"Nat Biotechnol"},{"key":"10.1038\/sj.mt.6300147_bib45","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2004-03-0798","article-title":"Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells","volume":"105","author":"De Palma","year":"2005","journal-title":"Blood"},{"key":"10.1038\/sj.mt.6300147_bib46","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1126\/science.1083413","article-title":"Transcription start regions in the human genome are favored targets for MLV integration","volume":"300","author":"Wu","year":"2003","journal-title":"Science"},{"key":"10.1038\/sj.mt.6300147_bib47","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.dci.2005.02.007","article-title":"Cloning, sequencing and characterization of lentiviral-mediated expression of rhesus macaque (Macaca mulatta) interleukin-2 receptor alpha cDNA","volume":"29","author":"Silvertown","year":"2005","journal-title":"Dev Comp Immunol"},{"key":"10.1038\/sj.mt.6300147_bib48","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science"},{"key":"10.1038\/sj.mt.6300147_bib49","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1749-6632.1999.tb08468.x","article-title":"Ex vivo expansion and genetic marking of primitive human and baboon hematopoietic cells","volume":"872","author":"Medin","year":"1999","journal-title":"Ann NY Acad Sci"},{"key":"10.1038\/sj.mt.6300147_bib50","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","article-title":"alpha-Galactosidase A deficient mice: a model of Fabry disease","volume":"94","author":"Ohshima","year":"1997","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500161631677X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500161631677X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T08:46:41Z","timestamp":1707900401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500161631677X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["S152500161631677X"],"URL":"https:\/\/doi.org\/10.1038\/sj.mt.6300147","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}